AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04222114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Description: The starting dose of catumaxomab for intra-peritoneal infusion will be 10μg, gradually increased to 20μg, 50μg and 150μg, respectively. From the second cycle, catumaxomab will be changed to 20μg,50μg,150μg on days 1,4 and 8.
Study NCT04222114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The treatment of investigator choice
Description: the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.
Study NCT00141661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04494700 - Low Dose Arm
Description: 30 mg loading dose for 6 days, followed by 10 mg daily
Study NCT00141661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04494700 - High Dose Arm
Description: 60 mg loading dose for 6 days, followed by 20 mg daily
Study NCT00141661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Matching placebo.
Study NCT02521181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lower Dose Sodium Bicarbonate
Description: Lower dose oral Sodium Bicarbonate (0.5 milliequivalents (mEq)/kg-LBW/day)
Study NCT02521181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher Dose Sodium Bicarbonate
Description: Higher dose oral Sodium Bicarbonate (0.8 mEq/kg-LBW/day)
Study NCT02521181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate
Study NCT00904748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate 100 mg CT
Description: sildenafil citrate 100 mg CT, single dose without water
Study NCT00904748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate 100 mg CT
Description: sildenafil citrate 100 mg CT, single dose with water
Study NCT00904748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viagra®
Description: sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
Study NCT01311401 — intervention group
Intervention type: OTHER
Intervention: NONE intervention
Description: NONE intervention
Study NCT04225572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy: Dependent on Patient's Needs
Description: Therapeutic exercise:~* ROM: Begin with passive upper extremity ROM and progress to active ROM.~* Strengthening: Progressive upper extremity resistive exercises starting with light weights.~* Aerobic: Select a suitable, individual aerobic exercise program (walking, yoga, etc.) Manual therapy~* Soft tissue mobilization, myofascial release, and stretching of identified tight and stiff tissue.~Lymphedema treatment~* Manual lymph drainage: Gentle lymphatic massage to lymph nodes and vessels by PT for 1-2 weeks. Instruct patient in self MLD to perform 1-2×/day for 10 minutes during the remaining weeks.~* Compression therapy: Gradient compression bandaging for daily wear with activities and exercise for 1-2 weeks. Instruct in self compression bandaging or issue a compression garment to wear with exercise or activity, or with worsening symptoms of AWS (i.e. cording extends down arm) or lymphedema.
Study NCT03580954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Stimulation or inhibition using TMS will be delivered guided by a neuronavigator system in different brain regions.
Study NCT03580954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Stimulation or inhibition using TMS will be delivered guided by a neuronavigator system in different brain regions.
Study NCT03239613 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: POHIM-CCRT
Description: postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
Study NCT04015167 — intervention group
Intervention type: DEVICE
Intervention: T2 Alpha Tibia Nailing System
Description: The T2 Alpha Tibia Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
Study NCT03959696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Notification
Description: Clinicians will be notified of their patients aged 76-85 with an upcoming, non urgent visit who are due for colorectal cancer screening.
Study NCT03959696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Notification
Description: Clinicians will be notified of their patients aged 76-85 with an upcoming, non urgent visit who are due for colorectal cancer screening.
Study NCT03959696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The 2-hour continuing medical education course in shared decision making, simulated patient interaction to practice skills, and monthly calls for a year to review difficult cases with clinical and shared decision making experts.
Study NCT03309644 — intervention group
Intervention type: OTHER
Intervention: Peripheral nerve blockade
Description: Participants who receive a peripheral nerve block identified through the medical chart.
Study NCT03309644 — intervention group
Intervention type: OTHER
Intervention: No peripheral nerve blockade
Description: Participants who did not receive a peripheral nerve block identified through the medical chart.
Study NCT04243096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-based Physical Therapy
Description: Exercises for pain modulation, strengthening, and neuromuscular control
Study NCT00565747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test culture
Description: A standard culture medium with added GM-CSF (ready-to-use)
Study NCT00565747 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control culture
Description: The same standard culture medium, but without any additions (ready-to-use)
Study NCT02918266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine subcutaneous injection
Study NCT02551588 — intervention group
Intervention type: PROCEDURE
Intervention: Valvular aortic stenosis surgery
Description: Dilatation of Valvular aortic stenosis
Study NCT04125602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat low carbohydrate diet
Description: Throughout the 6-day intervention, participants are provided with a high fat, low carbohydrate diet (HF-LCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25% respectively while the three macronutrients in the other 3-day diet account for 70%, 15% and 15% respectively. The sequencing of the two diets will be randomized.
Study NCT04125602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat high carbohydrate diet
Description: Throughout the 6-day intervention, participants are provided with a low fat, high carbohydrate diet (LF-HCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 20%, 15% and 65% respectively while the three macronutrients in the other 3-day diet account for 10%, 15% and 75% respectively. The sequencing of the two diets will be randomized.
Study NCT02940548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine GITS
Description: Nifedipine GITS 30\~60mg/day for 8 weeks
Study NCT02940548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine besylate
Description: Amlodipine besylate 5\~10mg/day for 8 weeks
Study NCT02358187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC
Description: Poly-ICLC is administered intramuscularly (i.m.) using sterile technique, as supplied from the vial, and in the amount prescribed for the participant's weight. Patients should receive a dose of acetaminophen (15 mg/kg up to a max of 1000 mg) 30-60 minutes before each poly-ICLC administration. The poly-ICLC treatments will be administered immediately following the vaccine. Patients/parents will be asked to report any temperature elevations and side effects after each treatment.
Study NCT04570202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: The EMDR therapy is organized in eight different phases, requiring attending multiple sessions, usually 12 separate sessions.
Study NCT01459120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Door-to-door
Description: Health workers propose the integrated service package including VCT at the peoples' homes (home-based testing).
Study NCT01459120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pitso
Description: Health care workers propose the integrated service package including VCT through community gatherings (Pitso).
Study NCT01101685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 7 days dosing of 10mg per day
Study NCT01101685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 days dosing at 10mg daily
Study NCT00356317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally informed therapy for schizophrenia (CIT-S)
Description: This family therapy consists of 15 video-taped, therapy sessions, each lasting approximately 75 minutes. The 15-session treatment will be broken down into five segments (each lasting approximately three sessions) with the following goals: 1) Fortify a strong sense of family unity; 2) educate about schizophrenia; 3) foster adaptive use of cultural, spiritual and/or existential beliefs in conceptualizing and coming to terms with schizophrenia; 4) teach effective communication training techniques; and 5) and teach useful problem solving strategies.
Study NCT00356317 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation treatment as usual
Description: This family therapy consists of three weekly sessions focusing on education about schizophrenia.
Study NCT04275817 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
Study NCT00538213 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: Single dose, Intramuscular injection
Study NCT00538213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's Influenza Vaccine GSK576389A
Description: Single dose, Intramuscular injection
Study NCT01505101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement
Description: MORE is a multimodal, dual-process group intervention involving mindfulness training, cognitive restructuring, and positive emotion induction. MORE consists of eight, weekly, two-hour group sessions led by a trained therapist.
Study NCT01505101 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Support Group (SG)
Description: The control arm will participate in a time-matched, conventional SG led by a Master's level therapist, discussing topics pertinent to chronic pain and opioid misuse. The SG format is adapted from the support group detailed in the evidence-based, Matrix Intensive Outpatient Treatment manual. The SG consists of eight, weekly, two-hour sessions.
Study NCT05307614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moksi® 400mg Tablet
Description: Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
Study NCT05307614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moksi® 400mg Tablet
Description: Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
Study NCT05307614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Avelox® 400Mg Tablet
Description: Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
Study NCT05307614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Avelox® 400Mg Tablet
Description: Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
Study NCT05714735 — intervention group
Intervention type: RADIATION
Intervention: Cerebral Venography
Description: Cerebral Venography Observation by DSA examinations
Study NCT02318381 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dissection of the superior transverse scapular ligament
Description: After treatment of the rotator cuff tear, the arthroscopic procedure will also proceed with the dissection of the superior transverse scapular ligament, in order to release pressure from the suprascapular nerve.
Study NCT04618458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power to Prevent
Description: Lifestyle diabetes prevention intervention based on the National Diabetes Prevention Program and tailored for African American families. The intervention will be delivered using telehealth and small group videoconferencing.
Study NCT01748318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: New Mexico Honey
Description: Apply 15 ml of NM Honey to CA-MRSA Abscess compare to standard antibiotic treatment
Study NCT01748318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Mexico Honey
Description: Apply 15 ml of NM Honey to CA-MRSA Abscess compare to standard antibiotic treatment
Study NCT01748318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bactrim DS
Description: Bactrim DS
Study NCT01748318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bactrim DS
Description: Bactrim DS
Study NCT04143919 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NYHA assessment
Description: The New York Heart Association (NYHA) functional classification of HF
Study NCT04143919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serum NT-proBNP concentration
Description: Subjects with NYHA score ≥ II will undergo a rapid, on site serum NT-proBNP test on the same day of the visit. Roche CARDIAC proBNP+ test, using the Cobas h 232 device, is a quantitative immunological test for the determination of NT-proBNP in heparinized venous blood.
Study NCT04143919 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transthoracic Ecocardiogram
Description: Subjects with a serum NT-proBNP result of ≥ 125 pg/mL at Visit 1 will be referred to a study cardiologist for a transthoracic echocardiogram to assess LVEF and relevant structural heart disease
Study NCT02918266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 DIC
Study NCT02519452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Subcutaneous (SC) Administration
Description: Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 and part 3 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
Study NCT02519452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
Description: Participants will receive Recombinant Human Hyaluronidase \[rHuPH20\]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
Study NCT02918266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet
Study NCT02830152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAAO
Description: The left atrial appendage is occluded with the AMPLATZER™ Amulet™ device, which offers a conformable disc and lobe designed for complete occlusion of the left atrial appendage.
Study NCT02830152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Therapy
Description: Available options included in Medical therapy are: anticoagulation with OAC or NOAC, antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
Study NCT05823350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: Abdominal massage after colonoscopy
Study NCT02787161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration
Description: High volume online HDF
Study NCT02787161 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis
Description: High-flux HD
Study NCT02305485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoVas BCS
Description: Subjects receiving NeoVas BCS
Study NCT02305485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE PRIME EECSS
Description: Subjects receiving XIENCE PRIME EECSS
Study NCT02651480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: Weekly instructions will be given to the participants in the intervention group about following vegan diet.
Study NCT02651480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Unrestricted diet with no instruction.
Study NCT02118935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Previously marketed cow's mlik-based infant formula
Study NCT02118935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marketed cow's milk-based infant formula with prebiotics
Study NCT03833102 — intervention group
Intervention type: OTHER
Intervention: biological analysis
Description: ST types will be determined for all individualized bacterial strains. For all the bacterial strains, RNAs expression will be analyzed at three different growth phases: early exponential phase, mid exponential phase and early stationary phase. Expression of RNAIII and SprD will be evaluated by quantitative polymerase chain reaction.
Study NCT01499108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Subcutaneous injection of liraglutide at doses of 0.6, 1.2, and 1.8 mg once daily during the 49 days duration of the study
Study NCT02869620 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT04408274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Processing Training
Study NCT04408274 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Study NCT02079324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-051
Description: intratumoral injection
Study NCT02669524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2409021
Study NCT02669524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2409021 placebo
Study NCT02669524 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Study NCT02669524 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: OGTT
Study NCT04448496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone implant
Description: Dexamethasone 0.7mg is injected into the vitreous cavity through the pars plana using applicator for diabetic macular edema.
Study NCT01501110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours
Study NCT04253353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: 61 mg capsule
Study NCT04253353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: 10 mg tablet
Study NCT02265406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Infective Agents
Study NCT02265406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03836924 — intervention group
Intervention type: DRUG
Intervention: Perampanel
Description: Perampanel tablets.
Study NCT03901391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Exome Sequencing
Description: Whole Exome Sequencing
Study NCT01584895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: A standard cardiac rehabilitation program consisting of 3 days per week of supervised exercise and education.
Study NCT00949988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib and Rituximab
Description: In Phase I, subjects will be enrolled into a 3+3 dose escalation scheme with two dasatinib cohort doses of 70 mg QD and 100 mg QD to be given continuously during each 28-day cycle. All subjects will also receive rituximab 500 mg/m2 on day 1 of each cycle (375 mg/m2 on day 1 of cycle 1 only). There will be a pre-phase for each dose cohort when subjects will receive single-agent dasatinib from days -7 to -1 to allow for PK and PD assessment. Cohorts will be assessed for dose-limiting toxicities for two cycles before accrual of additional
Study NCT06193031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16TR
Description: Administered as inhalation using a Philips Micro device inhaler.
Study NCT06193031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS) administered using Philips Micro device inhaler.
Study NCT06193031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyvaso®
Description: Administered as inhalation.
Study NCT02165514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lunar iDXA x-ray scan
Description: Subjects will lay either on their back or side depending whether subject has kyphosis or scoliosis. After the DEXA scan the computer will calculate the Cobb angle. The calculation of Cobb angle from the DEXA scan will be compared to the conventional spine x-ray.